Adage Capital Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $56.4M | Buy |
8,800,000
+3,102,395
| +54% | +$19.9M | 0.1% | 206 |
|
|
2025
Q1 | $20.2M | Buy |
+5,697,605
| New | +$20.2M | 0.04% | 411 |
|
|
2023
Q4 | – | Sell |
-1,700,200
| Closed | -$31.1M | – | 853 |
|
|
2023
Q3 | $31.1M | Buy |
1,700,200
+932,000
| +121% | +$17.1M | 0.07% | 289 |
|
|
2023
Q2 | $16.6M | Sell |
768,200
-239,136
| -24% | -$5.16M | 0.04% | 462 |
|
|
2023
Q1 | $29.6M | Sell |
1,007,336
-901,865
| -47% | -$26.5M | 0.07% | 322 |
|
|
2022
Q4 | $70.5M | Buy |
1,909,201
+559,201
| +41% | +$20.7M | 0.17% | 151 |
|
|
2022
Q3 | $38M | Buy |
1,350,000
+1,150,000
| +575% | +$32.4M | 0.09% | 230 |
|
|
2022
Q2 | $3.85M | Buy |
200,000
+162,800
| +438% | +$3.14M | 0.01% | 830 |
|
|
2022
Q1 | $478K | Buy |
+37,200
| New | +$478K | ﹤0.01% | 956 |
|